Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Patrizia Froesch"'
Autor:
Sabine Schmid, MD, Lisa Holer, MSc, Katrin Gysel, MSc, Kira-Lee Koster, MD, Sacha I. Rothschild, MD, Laura A. Boos, MD, Lorenz Frehner, MD, Sabine Cardoso Almeida, MD, Christian Britschgi, MD, PhD, Yannis Metaxas, MD, Michael Mark, MD, Patrizia Froesch, MD, Wolf-Dieter Janthur, MD, Anna Allemann, MD, Christine Waibel, MD, Catherine Von der Mühll-Schill, MD, Martin Früh, MD, Laetitia A. Mauti, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100735- (2024)
Objectives: On the basis of the positive results of CheckMate-743, first-line (1L) treatment of malignant pleural mesothelioma (MPM) with the combination of ipilimumab and nivolumab (ipi-nivo) has become a standard-of-care. Furthermore, patients who
Externí odkaz:
https://doaj.org/article/eaf1ac72cdcf42a0a92d67407c36e4ea
Autor:
Elona Cekani, Carolina Martorelli, Francesco Martucci, Miriam Patella, Stefano Cafarotti, Antonio Valenti, Stefania Freguia, Francesca Molinari, Patrizia Froesch, Milo Frattini, Anastasios Stathis, Luciano Wannesson
Publikováno v:
Swiss Medical Weekly, Vol 153, Iss 9 (2023)
BACKGROUND: The prognostic role of programmed death-ligand 1 (PD-L1) expression in patients with localised and locally advanced non-small cell lung cancer has not been fully elucidated. This information could help to better interpret recent and upcom
Externí odkaz:
https://doaj.org/article/a20c342a3bef452da551c9d053dbd235
Autor:
Francesco Martucci, Mariarosa Pascale, Maria Carla Valli, Gianfranco A. Pesce, Patrizia Froesch, Luca Giovanella, Antonella Richetti, Giorgio Treglia
Publikováno v:
Frontiers in Medicine, Vol 6 (2020)
Background: Molecular imaging methods are currently used in the management of patients with lung cancer. Compared to non-small cell lung cancer, less data are available about the impact of molecular imaging using fluorine-18-fluorodeoxyglucose positr
Externí odkaz:
https://doaj.org/article/6f1013b925504e0a89685554ec31c7e2
Publikováno v:
Translational Lung Cancer Research. 10:4303-4307
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05f6540155d1262b3fe63e7d3430074b
https://doi.org/10.21037/tlcr-21-802
https://doi.org/10.21037/tlcr-21-802
Autor:
Miklos Pless, Eric I. Eboulet, Martina Schneider, Martin Früh, Patrizia Froesch, Sacha I. Rothschild, Y. Metaxas, Luciano Wannesson, Susanne Weindler, Michael Schwitter, Nathalie Baudoux, Alfredo Addeo, Alex Friedlaender, Wolf-Dieter Janthur, Henning Burmeister, Michael Mark, Markus Joerger, Christine Biaggi-Rudolf
Publikováno v:
Cancer Immunology, Immunotherapy. 70:1255-1262
The safety of first-line (1L) durvalumab in patients with advanced nonsmall-cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 (PS2) is unknown. This is an interim unplanned safety analysis of the study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::483a60c292e3b4e5ac92e13cf756c8d9
https://doi.org/10.1007/s00262-020-02757-8
https://doi.org/10.1007/s00262-020-02757-8
Autor:
Patrizia Froesch, Francesco Petrella, Luciano Wannesson, Filippo Del Grande, Giuliana Giannetto, Stefania Rizzo
Publikováno v:
European Journal of Cancer Prevention. 29:321-328
Lung cancer prevention may include primary prevention strategies, such as corrections of working conditions and life style - primarily smoking cessation - as well as secondary prevention strategies, aiming at early detection that allows better surviv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f63beee1d872d14cb79d39c5e94bfd37
https://doi.org/10.1097/cej.0000000000000586
https://doi.org/10.1097/cej.0000000000000586
Autor:
Elona Cekani, Samantha Epistolio, Giulia Dazio, Marco Cefalì, Luciano Wannesson, Milo Frattini, Patrizia Froesch
Publikováno v:
Cancers. 14:4103
In non-small cell lung cancer (NSCLC) the most common alterations are identified in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene, accounting for approximately 30% of cases in Caucasian patients. The majority of mutations are located in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be5ffcc69e8619433b92720b83755058
https://doi.org/10.3390/cancers14174103
https://doi.org/10.3390/cancers14174103
Autor:
Elisabeth Oppliger Leibundgut, Sabine Schmid, Michael Mark, Ilaria Colombo, Oliver Gautschi, Gilles Godar, Martin Früh, Sacha I. Rothschild, Cristiana Sessa, Patrizia Froesch, David König, Corinne Rusterholz, Qiyu Li, Y. Metaxas
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 156
Background KRAS mutations are found in 20–25 % of non-squamous non-small cell lung cancer (NSCLC) and therapies targeting the RAS/MEK/ERK pathway are in development. We performed a multicenter open-label phase 1B trial to determine the recommended
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e4ea06d8f3787e511083e623b33199f
https://pubmed.ncbi.nlm.nih.gov/33933896
https://pubmed.ncbi.nlm.nih.gov/33933896
Autor:
Sacha I. Rothschild, Alfred Zippelius, Eric I. Eboulet, Spasenija Savic Prince, Daniel Betticher, Adrienne Bettini, Martin Früh, Markus Joerger, Didier Lardinois, Hans Gelpke, Laetitia A. Mauti, Christian Britschgi, Walter Weder, Solange Peters, Michael Mark, Richard Cathomas, Adrian F. Ochsenbein, Wolf-Dieter Janthur, Christine Waibel, Nicolas Mach, Patrizia Froesch, Martin Buess, Pierre Bohanes, Gilles Godar, Corinne Rusterholz, Michel Gonzalez, Miklos Pless, Swiss Group for Clinical Cancer Res Group
Publikováno v:
SSRN Electronic Journal.
Background: For patients with resectable stage IIIA(N2) non-small cell lung cancer (NSCLC) neoadjuvant chemotherapy with three cycles of cisplatin and docetaxel followed by surgery has been shown to yield a 1-year event-free survival (EFS) rate of 48
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12c18aa1447293402a94207100042f9c
https://doi.org/10.2139/ssrn.3759708
https://doi.org/10.2139/ssrn.3759708
Autor:
Michael, Mark, Patrizia, Froesch, Eric Innocents, Eboulet, Alfredo, Addeo, Miklos, Pless, Sacha I, Rothschild, Wolf-Dieter, Janthur, Henning, Burmeister, Alex, Friedlaender, Martina, Schneider, Yannis, Metaxas, Markus, Joerger, Luciano, Wannesson, Michael, Schwitter, Nathalie, Baudoux, Susanne, Weindler, Christine, Biaggi-Rudolf, Martin, Früh
Publikováno v:
Cancer immunology, immunotherapy : CII. 70(5)
The safety of first-line (1L) durvalumab in patients with advanced nonsmall-cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 (PS2) is unknown. This is an interim unplanned safety analysis of the study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::63930f4ea6b761ab7b6e9ee7ed7f803c
https://pubmed.ncbi.nlm.nih.gov/33130956
https://pubmed.ncbi.nlm.nih.gov/33130956